Patient-based drug discovery's latest news

Discover how Ksilink, myriamed and their spin-off Myrtil Biotechnologies implement deep learning to enhance high-content screening and deep-tissue phenotyping to identify...

Ksilink is dedicated to foster patient-based therapeutic approaches including personalized strategies as a means to stratify potential targeted therapies in a clinically relevant...

We will participate at this year’s Keystone Symposium on Modern Phenotypic Drug Discovery: From Chemical Biology to Therapy that will take place from May 22nd – May 25th 2022 in...

Ksilink proudly takes part of the EC funded EnvironMENTAL consortium. Want to know more? You are invited to join a series of seminars! EnvironMENTAL aims at identifying the...

Ksilink proudly announces the publication of exciting results in the journal “Cancer Biology & Therapy”. In fact, the technology for Personalized Functional Profiling (PFP) of...

A l'occasion de la journée de l'amitié franco-allemande, Ksilink vous présente ses meilleurs vœux pour l'année 2022 ! Version française Anlässlich des Tages der...

What you see here is neither a virtual firework nor has Ksilink become an expressionist. We took this beautiful picture, figuring the AI-based analysis of the pharmacological...

Ksilink is happy to announce the initiation of the ANR funded project "Target-agnostic drug discovery approaches for neuromuscular diseases (TREAD)". This project is supporting...

Ksilink is happy to have welcomed the team of Prof. Valérie Mezger-Lallemand from Université Didérot to initiate a collaboration with the aim to establish a new patient-based disease model to identify …